About Ollin Biosciences, Inc.
Ollin Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. Its lead candidate is OLN324, a VEGF/Ang2 bispecific antibody also known as IBI324. Ollin licensed OLN324 from Innovent Biologics, which discovered and is being developed in collaboration with Ollin. OLN324 is aimed at diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). In a randomized Phase 1b study it was compared head-to-head with Roche’s Vabysmo and showed better outcomes, and the company plans to start global Phase 3 trials in the second half of 2026. Its second program is OLN102, a bispecific antibody licensed from VelaVigo for thyroid eye disease and Graves’ disease, which is expected to enter into clinical development this year (2026). The company targets the global retina and ophthalmology markets. Founded in 2023, the company is headquartered in Austin, Texas, United States.